Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem in Subjects With Mild Dementia Due to Alzheimer's Disease (AD)

Trial Profile

XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem in Subjects With Mild Dementia Due to Alzheimer's Disease (AD)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs UE 2343 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Proof of concept; Therapeutic Use
  • Acronyms XanADu
  • Sponsors Actinogen Medical
  • Most Recent Events

    • 20 Jul 2023 Results assessing the effects of Xanamem on cognition from XanaHES (n= 42, 20 mg) and XanaMIA (n=105, 5 & 10 mg) and XanADu-X biomarker extension study (n=72, 10 mg), presented at the Alzheimer's Association International Conference 2023.
    • 30 Mar 2023 Results published in the Actinogen Medical Media Release.
    • 30 Mar 2023 According to Actinogen media release, CEO Dr. Dana Hilt will make an oral presentation to the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (ADPD 2023).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top